Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Eur Rev Med Pharmacol Sci ; 23(21): 9313-9320, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31773698

ABSTRACT

OBJECTIVE: In this study, we aimed to investigate the relation between the mRNA expression levels of VHL, TIMP-3 and RASSF1A genes, and the histopathological and clinical characteristics of patients with renal tumors. PATIENTS AND METHODS: Radical nephrectomy specimens of cases presented without neoadjuvant treatment were confirmed to be cancerous, non-cancerous, benign, and healthy after removal from separate localizations. A total of 69 patients with kidney tumors (138 tissue samples) were included in the study group. RNA isolation, reverse transcriptase PCR (RT-PCR), and quantitative real time PCR (qPCR) were performed, and the GAPDH gene was used to normalize mRNA levels. RESULTS: In the RCC cancerous tissue, TIMP-3 levels increased 1.3 times and RASSF1A levels increased 1.4 times compared to the corresponding levels in non-cancerous tissues, and there was no statistically significant difference in these values. On the other hand, VHL gene expression levels in cancerous tissue were 2.8 times higher than in matched adjacent non-cancerous tissues (p < 0.05). In the case of oncocytomas, TIMP-3 levels were found to be 3.2 times higher, RASSF1A levels 3.8 times higher, and VHL levels 2.2 times lower than the corresponding levels in healthy tissues (p < 0.05). CONCLUSIONS: The roles of VHL, TIMP-3, and RASSF1A mRNA expression in contributing to the development of renal tumors could not be clearly established. Further studies are therefore required to elucidate the mechanisms underlying renal tumors.


Subject(s)
Carcinoma, Renal Cell/metabolism , Gene Expression Regulation, Neoplastic/genetics , Kidney Neoplasms/metabolism , Tissue Inhibitor of Metalloproteinase-3/biosynthesis , Tumor Suppressor Proteins/biosynthesis , Von Hippel-Lindau Tumor Suppressor Protein/biosynthesis , Adolescent , Adult , Aged , Carcinoma, Renal Cell/genetics , Case-Control Studies , Female , Humans , Kidney Neoplasms/genetics , Male , Middle Aged , Transcriptome/genetics , Young Adult
2.
Z Rheumatol ; 76(5): 458-460, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28197771

ABSTRACT

Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by lymphocytic and plasmacytic infiltration of the exocrine glands. Tubulointerstitial nephritis (TIN) is the most common type of renal involvement in pSS. However, clinically significant renal involvement is uncommon. Granulomatous interstitial nephritis (GIN) is a rare histopathological entity characterized by the presence of granulomas against a background of interstitial inflammation. GIN is not a typical and commonly seen form of TIN in pSS. Herein, we report on a patient who was concurrently diagnosed with pSS and GIN and was treated successfully with rituximab (RTX). pSS should be considered in the differential diagnosis of GIN, and RTX may be a good option in the treatment of this patient group.


Subject(s)
Glomerulonephritis/drug therapy , Glomerulonephritis/pathology , Nephritis, Interstitial/drug therapy , Nephritis, Interstitial/pathology , Rituximab/administration & dosage , Sjogren's Syndrome/drug therapy , Sjogren's Syndrome/pathology , Adult , Anti-Inflammatory Agents/administration & dosage , Diagnosis, Differential , Female , Humans , Immunologic Factors/administration & dosage , Treatment Outcome
3.
Andrologia ; 46(8): 910-6, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24117927

ABSTRACT

We aimed to investigate the impact of various varicocelectomy techniques and/or L-carnitine as an adjunct treatment, following the emergence of oxidative stress, on the expression levels of SCF/c-kit signalling pathways in spermatogenesis. Forty-two rats were divided into seven groups: group 1 (G1) control; group 2 (G2) sham; group 3 (G3) varicocele; group 4 (G4) varicocele + varicocelectomy with testicular nonartery sparing; group 5 (G5) same as G4 but with artery sparing; group 6 (G6) same as G4 but with L-carnitine and group 7 (G7) same as G5 with L-carnitine. mRNA expression levels of SCF and c-kit were measured quantitatively using real-time polymerase chain reaction. CASP-3 activity at protein level was determined, and histological evaluation was performed. mRNA expression level of SCF increased in G6 as compared to control group (3.52-folds change; P = 0.035), whereas mRNA expression level of c-kit gene remained the same. We found that in the left testis of G6 group, mRNA expression level of SCF increased 2.2-folds in comparison with the right testis (P < 0.05). There were no statistically significant differences in the CASP-3 protein expression levels between the control and other groups. When Cosentino Score analyses of immunostaining were conducted, we observed no significant differences among groups. Spermatogenic failure could be primarily due to a sertoli cell dysfunction. Although surgical treatment has been the best option for management of varicocele, auxiliary agents like L-carnitine may be considered as supportive treatment regimes in addition to conventional surgical treatments.


Subject(s)
Carnitine/therapeutic use , Stem Cell Factor/metabolism , Urologic Surgical Procedures, Male/methods , Varicocele/surgery , Vitamin B Complex/therapeutic use , Animals , Chemotherapy, Adjuvant , Male , Oxidative Stress , Random Allocation , Rats, Wistar , Spermatogenesis , Varicocele/drug therapy
4.
Transplant Proc ; 45(1): 185-9, 2013.
Article in English | MEDLINE | ID: mdl-23375296

ABSTRACT

We analyzed 25 pediatric renal transplantation patients on sirolimus (SRL) therapy to assess changes in serum creatinine, glomerular filtration rate, electrolytes, triglycerides, cholesterol, and side effects. Mean time to initiate SRL therapy was 3.2 years. The serum creatinine levels of patients on SRL treatment at 1, 6, 12, and 24 months were 1.67 ± 1.15 mg/dL, 1.18 ± 0.52 mg/dL, 1.24 ± 0.32 mg/dL, 1.15 ± 0.31 mg/dL, and 1.17 ± 0.12 mg/dL, respectively. We observed proteinuria in 3, hyperlipidemia in 5, and anemia in 2 patients, but none had the treatment discontinued. We diagnosed interstitial pneumonia in (n = 1), nasal acneiform lesions (n = 1), and lower extremity edema (n = 1). Hypokalemia developed in 1 subject with high blood SRL levels. In the follow-up period there was no case of acute rejection episode during SRL therapy.


Subject(s)
Kidney Failure, Chronic/complications , Kidney Failure, Chronic/drug therapy , Kidney Transplantation/methods , Sirolimus/adverse effects , Adolescent , Child , Cholesterol/metabolism , Creatinine/blood , Female , Glomerular Filtration Rate , Graft Survival , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Kidney/pathology , Kidney Failure, Chronic/surgery , Living Donors , Male , Sirolimus/therapeutic use , Steroids/therapeutic use , Time Factors , Tissue Donors , Treatment Outcome , Triglycerides/metabolism , Young Adult
5.
J BUON ; 14(4): 703-6, 2009.
Article in English | MEDLINE | ID: mdl-20148466

ABSTRACT

Primary pure small cell carcinoma of the urinary bladder (SCCB) is an extremely rare tumor and accounts for less than 1% of all malignant tumors of the urinary bladder. This tumor exhibits more aggressive behavior than bladder transitional cell carcinoma. Unfortunately, optimal treatment strategy for this malignancy is still unknown. We present a patient with metastatic primary pure SCCB (stage IV) who responded to carboplatin plus etoposide combination chemotherapy and discuss the relevant current literature.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Small Cell/drug therapy , Urinary Bladder Neoplasms/drug therapy , Aged , Carboplatin/administration & dosage , Carcinoma, Small Cell/pathology , Etoposide/administration & dosage , Humans , Male , Prognosis , Treatment Outcome , Urinary Bladder Neoplasms/pathology
6.
J Inherit Metab Dis ; 31 Suppl 2: S255-9, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18392749

ABSTRACT

We report a 13-year-old boy with multisystem involvement secondary to accumulation of amylopectin-like material. He was born to consanguineous parents at full term without any complications and his maternal perinatal history was uneventful. His parents were cousins. He had normal growth and development except for his weight. His sister died from an unexplained cardiomyopathy at the age of 8 years. Our patient's initial symptom was severe heart failure. Since he also had a complaint of muscle weakness, electromyography was performed which showed muscle involvement. The diagnosis was suggested by tissue biopsy of skeletal muscle showing intracellular, basophilic, diastase-resistant, periodic acid-Schiff-positive inclusion bodies and was confirmed by the presence of a completed branching enzyme deficiency. Similar intracytoplasmic inclusion-like bodies were also found in liver biopsy, but very few in number compared with the skeletal muscle. The patient died from an intercurrent infection. Postmortem endomyocardial biopsy revealed the same intracytoplasmic inclusions as described above affecting almost all myocardial cells. Ultrastructural examination of liver biopsy was nondiagnostic; however, myocardium showed prominent, large, intracytoplasmic deposits. Glycogen branching enzyme gene sequence was normal, and thus classical branching enzyme deficiency was excluded. Our patient represents the first molecular study performed on a patient in whom there was multiple system involvement secondary to accumulation of amylopectin-like material. We suggest that this is an as yet undefined and different phenotype of glycogen storage disease associated with multisystemic involvement.


Subject(s)
1,4-alpha-Glucan Branching Enzyme/deficiency , Amylopectin/biosynthesis , Glycogen Storage Disease Type IV/complications , Inclusion Bodies/enzymology , Liver/enzymology , Muscle, Skeletal/enzymology , Myocardium/enzymology , 1,4-alpha-Glucan Branching Enzyme/genetics , Adolescent , Autopsy , Biopsy , Electromyography , Fatal Outcome , Genotype , Glycogen Storage Disease Type IV/diagnosis , Glycogen Storage Disease Type IV/enzymology , Glycogen Storage Disease Type IV/genetics , Glycogen Storage Disease Type IV/pathology , Heart Failure/enzymology , Heart Failure/etiology , Humans , Inclusion Bodies/pathology , Liver/pathology , Male , Muscle Weakness/enzymology , Muscle Weakness/etiology , Muscle, Skeletal/pathology , Myocardium/pathology , Phenotype , Up-Regulation
7.
J Exp Clin Cancer Res ; 23(4): 625-31, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15743033

ABSTRACT

In response to DNA damage, p53 accumulates and regulates expression of several genes, including cyclin-dependent kinase inhibitor p21. Cells then undergo p21 dependent cell cycle arrest, which allows DNA damage repair and apoptosis. Bax is a death promoter member of the bcl-2 family which plays a central role in the regulation and commitment to programmed cell death. Breslow thickness is the most important factor in predicting prognosis for cutaneous malignant melanoma. In order to define the role of cyclin dependent kinase inhibitors and apoptosis regulators in invasion of malignant melanoma we investigated the expression of p21 and bax proteins. We observed that significant high p21 expression was associated with increasing Breslow thickness (Spearman correlation analysis, p=0.01). Additionally, Clark level I and II tumours expressed significantly lower p21 positivity than Clark level III, IV and V (p=0.006). Similarly, thick tumors showed a higher bax expression (p=0.012). Our results suggested that the role of p21 expression is more complicated in melanocytic skin cancers and abnormal regulation or abnormal function of cell cycle regulators occurred in the development and progression of malignant melanoma. In order to understand the role of bax expression in thick malignant melanomas and invasion biology, comparative analytic studies with other apoptosis regulators are needed.


Subject(s)
Cell Cycle Proteins/biosynthesis , Cell Cycle Proteins/physiology , DNA Damage , Gene Expression Regulation, Neoplastic , Melanoma/diagnosis , Melanoma/metabolism , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins c-bcl-2/physiology , Skin Neoplasms/diagnosis , Skin Neoplasms/metabolism , Adult , Aged , Apoptosis , Cell Cycle , Cell Nucleus/metabolism , Cyclin-Dependent Kinase Inhibitor p21 , Cytoplasm/metabolism , Female , Humans , Immunohistochemistry , Male , Melanoma/pathology , Middle Aged , Prognosis , Proto-Oncogene Proteins c-bcl-2/metabolism , bcl-2-Associated X Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...